Page 1 | Search Results | Hematology, ASH Education Program

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Common variable immune deficiency: case studies

Charlotte Cunningham-Rundles

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 449–456.

https://doi.org/10.1182/hematology.2019002062

Published: 2019

Journal Articles

Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN

Aaron T. Gerds

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 407–414.

https://doi.org/10.1182/hematology.2019000048

Published: 2019

Journal Articles

Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond

Claire N. Harrison, Donal P. McLornan

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 489–497.

https://doi.org/10.1182/asheducation-2017.1.489

Published: 2017

Journal Articles

Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs)

Naveen Pemmaraju, Ruben Mesa

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 649–651.

https://doi.org/10.1182/asheducation-2015.1.649

Published: 2015

Journal Articles

Management of prolymphocytic leukemia

Claire Dearden

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 361–367.

https://doi.org/10.1182/asheducation-2015.1.361

Published: 2015

Journal Articles

Management of symptoms in polycythemia vera and essential thrombocythemia patients

Deepti Radia, Holly L. Geyer

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 340–348.

https://doi.org/10.1182/asheducation-2015.1.340

Published: 2015

Journal Articles

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Holly L. Geyer, Ruben A. Mesa

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 277–286.

https://doi.org/10.1182/asheducation-2014.1.277

Published: 2014

Journal Articles

Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

David T. Yeung, Michael J. Mauro

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 240–243.

https://doi.org/10.1182/asheducation-2014.1.240

Published: 2014

Journal Articles

JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside

Jason Gotlib

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 529–537.

https://doi.org/10.1182/asheducation-2013.1.529

Published: 2013

Journal Articles

The many faces of common variable immunodeficiency

Charlotte Cunningham-Rundles

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 301–305.

https://doi.org/10.1182/asheducation.V2012.1.301.3798316

Published: 2012

Journal Articles

The many faces of marginal zone lymphoma

Pier Luigi Zinzani

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 426–432.

https://doi.org/10.1182/asheducation.V2012.1.426.3798535

Published: 2012

Journal Articles

Management of Myelofibrosis

Alessandro M. Vannucchi

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 222–230.

https://doi.org/10.1182/asheducation-2011.1.222

Published: 2011

Journal Articles

Assessing New Therapies and Their Overall Impact in Myelofibrosis

Ruben A. Mesa

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 115–121.

https://doi.org/10.1182/asheducation-2010.1.115

Published: 2010

Journal Articles

Therapeutic potential of JAK2 inhibitors

Srdan Verstovsek

Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 636–642.

https://doi.org/10.1182/asheducation-2009.1.636

Published: 2009

Journal Articles

Hemophagocytic lymphohistiocytosis (HLH) and related disorders

Alexandra H. Filipovich

Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 127–131.

https://doi.org/10.1182/asheducation-2009.1.127

Published: 2009

Journal Articles

Chronic Myeloproliferative Disorders

Jerry L. Spivak, Giovanni Barosi, Gianni Tognoni, Tiziano Barbui, Guido Finazzi, Roberto Marchioli, Monia Marchetti

Hematology Am Soc Hematol Educ Program (2003) 2003 (1): 200–224.

https://doi.org/10.1182/asheducation-2003.1.200

Published: 2003

Journal Articles

A Polycythemia Vera Update: Diagnosis, Pathobiology, and Treatment

Thomas C. Pearson, Maria Messinezy, Nigel Westwood, Anthony R. Green, Anthony J. Bench, Anthony R. Green, Brian J.P. Huntly, Elizabeth P. Nacheva, Tiziano Barbui, Guido Finazzi

Hematology Am Soc Hematol Educ Program (2000) 2000 (1): 51–68.

https://doi.org/10.1182/asheducation.V2000.1.51.51

Published: 2000

NARROW

Common variable immune deficiency: case studies

Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN

Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond

Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs)

Management of prolymphocytic leukemia

Management of symptoms in polycythemia vera and essential thrombocythemia patients

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside

The many faces of common variable immunodeficiency

The many faces of marginal zone lymphoma

Management of Myelofibrosis

Assessing New Therapies and Their Overall Impact in Myelofibrosis

Therapeutic potential of JAK2 inhibitors

Hemophagocytic lymphohistiocytosis (HLH) and related disorders

Chronic Myeloproliferative Disorders

A Polycythemia Vera Update: Diagnosis, Pathobiology, and Treatment

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only